• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Treatment Patterns and Outcomes of Patients Receiving Direct Oral Anticoagulants or Low Molecular Weight Heparin who Experienced Life-threatening Intracranial Hemorrhage (P5.053)
Conclusions:This study provides a real-world picture of patients receiving FXa inhibitors or LMWH, experiencing life-threatening intracranial bleeds. Despite efforts to restore hemostasis, mortality remained high and substantial healthcare resources were expended. This highlights the need to develop specific strategies for management of ICH in this patient population.Study Supported by: Portola Pharmaceuticals, Inc.Disclosure: Dr. Milling has received personal compensation for activities with CSI Behring, Janssen, BI, and Portola. Dr. Feronti has received research support from Portola. Dr. Clark has received research perso...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Milling, T. J., Feronti, C., Clark, C. L., Fermann, G. J., Song, S. S., Torbati, S. S., Weiss, J., Patel, D., Neuman, W. R. Tags: Neurocritical Care: Intracerebral Hemorrhage Source Type: research

Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study Brief Reports
Conclusion— Extended-duration thromboprophylaxis with enoxaparin was associated with reduced venous thromboembolism risk and increased major bleeding in the subgroup of patients with ischemic stroke in the EXCLAIM study. Clinical Trial Registration Information— URL: http://clinicaltrials.gov. Unique Identifier: NCT00077753.
Source: Stroke - December 24, 2012 Category: Neurology Authors: Turpie, A. G. G., Hull, R. D., Schellong, S. M., Tapson, V. F., Monreal, M., Samama, M.-M., Chen, M., Yusen, R. D., for the EXCLAIM Investigators Tags: Cerebrovascular disease/stroke, Deep vein thrombosis, Anticoagulants Brief Reports Source Type: research